138 reports of this reaction
1.4% of all VONOPRAZAN FUMARATE reports
#18 most reported adverse reaction
CARDIAC FAILURE is the #18 most commonly reported adverse reaction for VONOPRAZAN FUMARATE. There are 138 FDA adverse event reports linking VONOPRAZAN FUMARATE to CARDIAC FAILURE. This represents approximately 1.4% of all 9,763 adverse event reports for this drug.
Patients taking VONOPRAZAN FUMARATE who experience cardiac failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC FAILURE is a less commonly reported adverse event for VONOPRAZAN FUMARATE, but still significant enough to appear in the safety profile.
In addition to cardiac failure, the following adverse reactions have been reported for VONOPRAZAN FUMARATE:
The following drugs have also been linked to cardiac failure in FDA adverse event reports:
CARDIAC FAILURE has been reported as an adverse event in 138 FDA reports for VONOPRAZAN FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC FAILURE accounts for approximately 1.4% of all adverse event reports for VONOPRAZAN FUMARATE, making it a notable side effect.
If you experience cardiac failure while taking VONOPRAZAN FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.